 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5390 News |  |
| «12345678910111213...6970» |
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with metastatic HER2 positive breast cancer (JCOG1607 HERB TEA study) () - Jan 22, 2024 - Abstract #YIR2024YIR_89;
However, T-DM1 showed better tolerability in terms of frequency and severity of adverse events. HPD will continue to be the standard of care as the first-line treatment for older patients with HER2-positive metastatic breast cancer.
- ||||| PERT-IJS (pertuzumab biosimilar) / Biocon
Trial initiation date, Metastases: Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta (clinicaltrials.gov) - Jan 21, 2024
P3, N=382, Not yet recruiting, Sponsor: Biocon Biologics UK Ltd
HPD will continue to be the standard of care as the first-line treatment for older patients with HER2-positive metastatic breast cancer. Initiation date: Dec 2023 --> Mar 2024
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Retrospective data, Journal, Metastases: Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials. (Pubmed Central) - Jan 20, 2024
Monochemotherapy (Docetaxel) plus dual-target (Trastuzumab and Pertuzumab) therapy remains the optimal choice among all first-line treatment options for ABC. The combination of trastuzumab with TKIs (Pyrotinib) demonstrated a significant improvement in PFS and ORR, but further data are warranted to confirm the survival benefit.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Pruritus related to trastuzumab and pertuzumab in HER2?+?breast cancer patients. (Pubmed Central) - Jan 15, 2024
The combination of trastuzumab with TKIs (Pyrotinib) demonstrated a significant improvement in PFS and ORR, but further data are warranted to confirm the survival benefit. Pruritus is uncommon in patients on trastuzumab and pertuzumab, generally a chronic condition, with gabapentinoids or antihistamines representing effective therapies.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Preclinical, Journal: Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. (Pubmed Central) - Jan 15, 2024
Finally, proteomic analysis confirmed a significant change in the abundance patterns of more than 600 proteins with implications in key biological processes, such as ribosome formation, mitochondrial activity, and metabolism, which could be relevant mechanisms in the generation of resistance in HER2-positive breast cancer. We concluded that these resistant BCCLs may be a valuable tool to better understand the mechanisms of acquisition of resistance to trastuzumab and pertuzumab-based anti-HER2 therapy.
- || DHES0815A / Roche
P1 data, Preclinical, Journal, Metastases: The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. (Pubmed Central) - Jan 11, 2024
P1
To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzumab for binding, conjugated to a reduced potency PBD (pyrrolobenzodiazepine) dimer payload...A dose-escalation study (ClinicalTrials.gov: NCT03451162) in patients with HER2-positive metastatic breast cancer, with the primary objective of evaluating the safety and tolerability of DHES0815A and secondary objectives of characterizing the pharmacokinetics, objective response rate, duration of response, and formation of anti-DHES0815A antibodies, is reported herein. Despite early signs of anti-tumor activity, patients at higher doses develop persistent, non-resolvable dermal, ocular, and pulmonary toxicities, which led to early termination of the phase 1 trial.
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline. (Pubmed Central) - Jan 11, 2024
It is ASCO's view that healthcare providers and system decision-makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, Journal: A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems (CSBrS-026). (Pubmed Central) - Jan 11, 2024
Different HER2 expression statuses and HR expression statuses are correlated with the pCR rate after dual-target neoadjuvant therapy in HER2+ breast cancer patients. There is a relatively good consistency between Miller-Payne and RCB systems in evaluating the pathologic efficacy of neoadjuvant therapy for HER2+ breast cancer.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Review, Journal, Metastases: Systemic Therapies for HER2-Positive Advanced Breast Cancer. (Pubmed Central) - Jan 11, 2024
In this article, we review the currently available clinical data informing the effective management of HER2-positive breast cancer beyond standard first-line therapy with pertuzumab, trastuzumab, and taxanes, and the management of relapse in patients who have already been exposed to both these agents and T-DM1 for early breast cancer (EBC). We additionally discuss novel anti-HER2 targeted agents and combinations in clinical trials, which may be integrated into standard treatment paradigms in the future.
- | paclitaxel / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (clinicaltrials.gov) - Jan 11, 2024
P2, N=249, Active, not recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
We additionally discuss novel anti-HER2 targeted agents and combinations in clinical trials, which may be integrated into standard treatment paradigms in the future. Trial primary completion date: Dec 2023 --> Jun 2024
- || Tukysa (tucatinib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study (clinicaltrials.gov) - Jan 11, 2024
P1, N=30, Recruiting, Sponsor: The Netherlands Cancer Institute
Trial primary completion date: Dec 2023 --> Jun 2024 Not yet recruiting --> Recruiting
- | Perjeta (pertuzumab) / Roche
New trial: RADIOCOM: Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (clinicaltrials.gov) - Jan 9, 2024
P=N/A, N=148, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2/HER3-specific vs. pan-HER targeting strategies. (Pubmed Central) - Jan 9, 2024
Not yet recruiting --> Recruiting Our findings indicate that pan-HER inhibition including HER4 and EGFR blockade is more effective than selectively targeting HER3 or HER2-HER3 in NRG1 fusion-positive cancers.
- || albumin-bound paclitaxel / Generic mfg.
P2 data, Journal: A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer. (Pubmed Central) - Jan 8, 2024
P2
Our findings indicate that pan-HER inhibition including HER4 and EGFR blockade is more effective than selectively targeting HER3 or HER2-HER3 in NRG1 fusion-positive cancers. Brecan study demonstrated the encouraging safety and efficacy of neoadjuvant PLD/C/HP-nabP/HP, suggesting a potential therapeutic option in HER2-positive BC.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, P2 data, Journal: The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial. (Pubmed Central) - Jan 4, 2024
P2/3
sTK1 activity increased following neoadjuvant therapy for HER2-positive BC but was not associated with patient outcomes or treatment benefit. However, the post-surgery prognostic value in patients that have not attained pCR warrants further investigation.
- | Balversa (erdafitinib) / J&J, Perjeta (pertuzumab) / Roche
Journal: Adipocyte precursor-derived NRG1 promotes resistance to FGFR inhibition in urothelial carcinoma. (Pubmed Central) - Jan 4, 2024
Remarkably, data from single-cell RNA-sequencing revealed that NRG1 was enriched in platelet-derived growth factor receptor-A (PDGFRA) expressing inflammatory cancer-associated fibroblasts, which is also expressed on adipocyte precursors. Together, this work reveals a paracrine mechanism of anti-FGFR resistance in bladder cancer, and potentially other cancers, that is amenable to inhibition using available targeted therapies.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Phase classification, Trial primary completion date, Combination therapy, Metastases: Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer (clinicaltrials.gov) - Jan 3, 2024
P2, N=16, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Together, this work reveals a paracrine mechanism of anti-FGFR resistance in bladder cancer, and potentially other cancers, that is amenable to inhibition using available targeted therapies. Phase classification: P2a --> P2 | Trial primary completion date: Dec 2023 --> Jun 2024
- | Perjeta (pertuzumab) / Roche
Journal: Design, synthesis and bioactivity evaluation of novel fusion peptides and their CPT conjugates inducing effective anti-tumor responses on HER2 positive tumors. (Pubmed Central) - Jan 2, 2024
Pertuzumab, as the first monoclonal antibody inhibitor of HER2 dimerization, has been FDA-approved for HER2-positive patients...In vivo studies demonstrated that compound 4 possesses superior anti-tumor activity compared to CPT and can effectively mitigate potential renal toxicity associated with free SMAC peptides. In conclusion, conjugate 4 exhibited excellent anti-tumor activity both in vitro and in vivo, offering potential for further development as a novel peptide-conjugated drug.
- | Trial primary completion date, Metastases: Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jan 1, 2024
P2, N=25, Not yet recruiting, Sponsor: Mayo Clinic
In conclusion, conjugate 4 exhibited excellent anti-tumor activity both in vitro and in vivo, offering potential for further development as a novel peptide-conjugated drug. Trial primary completion date: Aug 2024 --> Aug 2025
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Retrospective data, Journal, Metastases: Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis. (Pubmed Central) - Dec 31, 2023
P=N/A
Toxicities were tolerable in both groups. (ClinicalTrials.gov: NCT05572645).
- Keytruda (pembrolizumab) / Merck (MSD), Perjeta (pertuzumab) / Roche
Change in Biomarker Profile after neoadjuvant chemotherapy is especially common in patients with HER2+ breast cancer subtype () - Dec 29, 2023 - Abstract #SSO2024SSO_410;
Biomarker changes in 18.7% of our study cohort confirms the need for biomarker retesting in those with residual disease, and especially among those with HER2+ tumors. Investigations on whether biomarker profile change after NAC is associated with differential outcomes or impact of adjuvant therapy is ongoing.
- || Review, Journal, Metastases: Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma. (Pubmed Central) - Dec 29, 2023
In this review, we provided an in-depth overview of the advances in the research regarding HER2-targeted therapy and the role of HER2 in mUC. Furthermore, we also discussed the prospects of potential strategies aimed at overcoming anti-HER2 resistance, and summarize the novel anti-HER2 approaches for the management of mUC used in recent clinical trials.
- || Review, Journal: HER2-targeted therapies for salivary gland cancers. (Pubmed Central) - Dec 25, 2023
Anti-HER2 treatment strategy is emerging as potentially effective in selected HER2 overexpressing SGCs. However, prospective and multicentric clinical trials are needed to evaluate the efficacy of these therapeutic regimens within larger cohorts and to assess the most appropriate treatment sequence strategy.
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: Survival, treatment patterns, and costs of HER2+?metastatic breast cancer patients in Ontario between 2005 to 2020. (Pubmed Central) - Dec 21, 2023
However, the mOS observed for 2L T-DM1 was shorter than that found in pivotal, clinical trial literature. As expected, anti-cancer systemic therapy costs were the main contributor to the over quarter-million dollar mean cost per patient on pert_tras in 1L.
- |||| Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
New P2 trial, Combination therapy: DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer (clinicaltrials.gov) - Dec 20, 2023
P2, N=80, Not yet recruiting, Sponsor: RemeGen Co., Ltd.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy: R2D2: Her2-positive Lung Cancer Treated With Dedicated Drug (clinicaltrials.gov) - Dec 19, 2023
P2, N=46, Completed, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
As expected, anti-cancer systemic therapy costs were the main contributor to the over quarter-million dollar mean cost per patient on pert_tras in 1L. Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results. (Pubmed Central) - Dec 19, 2023
Notably, HER2 amplification level had a predictive role regardless of IHC results. Even in patients with HER2 protein expression of 3+, treatment outcome to HER2-directed therapy was dependent on the level of HER2 gene amplification.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Machine learning: Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2-positive breast cancer patients: A machine learning approach. (Pubmed Central) - Dec 17, 2023
Even in patients with HER2 protein expression of 3+, treatment outcome to HER2-directed therapy was dependent on the level of HER2 gene amplification. Our results seem worthy of further investigation in large validation studies and this work could be the basis of future study that will also involve radiomics analysis of biomedical images.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, FDG PET: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - Dec 14, 2023
P2, N=377, Completed, Sponsor: MedSIR
Our results seem worthy of further investigation in large validation studies and this work could be the basis of future study that will also involve radiomics analysis of biomedical images. Active, not recruiting --> Completed
- || Tukysa (tucatinib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial: Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study (clinicaltrials.gov) - Dec 7, 2023
P1, N=30, Not yet recruiting, Sponsor: The Netherlands Cancer Institute
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date: NeoTOP: Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status (clinicaltrials.gov) - Dec 7, 2023
P2, N=86, Active, not recruiting, Sponsor: UNICANCER
Active, not recruiting --> Completed Trial completion date: Jun 2023 --> Jun 2024
- | Nerlynx (neratinib) / Puma, Perjeta (pertuzumab) / Roche
Phase classification, Metastases: Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Dec 7, 2023
P1/2, N=43, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2023 --> Jun 2024 Phase classification: P1b --> P1/2
- Tukysa (tucatinib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Identification of MAPK and mTOR pathway alterations in HER2-amplified colorectal cancer. (Level 1, West Hall; Poster Bd # L13) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_829;
These somatic events appear to be more common in HER2-amplified colon cancer than rectal cancer. Next generation based molecular profiling is recommended to identify potential resistance mechanisms before initiation of HER2-directed therapy.
- Early identification and treatment of occult metastatic disease in stage III colon cancer (SU2C ACT3 clinical trial). (Level 1, West Hall; Poster Bd # J14) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_793;
P3
90% of ctDNA+ patients did not have an actionable biomarker. Strict windows for eligibility and enrollment initially restricted eligibility but these were adjusted to increase eligibility.
- | 5-fluorouracil / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Journal: The Add-On Effect of Fluorouracil, Epirubicin, and Cyclophosphamide Regimens for Neoadjuvant Chemotherapy in Human Epidermal Receptor 2 (HER2)-Positive Breast Cancer: A Single-Center Retrospective Study. (Pubmed Central) - Dec 6, 2023
This study suggests an unlikely add-on effect of an anthracycline-based regimen for NAC in HER2-positive breast cancer. Moreover, our results support that the pCR rate is high in patients with hormone receptor-negative, HER2-positive breast cancer.
- || Cipterbin (inetetamab) / 3SBio
Clinical data, Journal, Metastases: Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody. (Pubmed Central) - Dec 5, 2023
Moreover, our results support that the pCR rate is high in patients with hormone receptor-negative, HER2-positive breast cancer. Inetetamab demonstrates effectiveness with a manageable safety profile, offering a promising therapeutic option for HER2-positive breast cancer patients who have shown resistance to prior anti-HER2 treatments.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer. (Pubmed Central) - Dec 5, 2023
However, intensive systemic treatment is required for advanced diseases (C/D). Selective de-intensified RNI and intensified systemic treatment should be investigated in future studies.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Review, Journal: Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature. (Pubmed Central) - Dec 5, 2023
We conclude that reduced HER2 expression by IHC following neoadjuvant treatment was associated with lower recurrence rates in HER2 IHC 3+ breast cancer. If confirmed, RD HER2 IHC expression could be used as a prognostic biomarker to stratify patients in adjuvant trials and identify patients who may benefit from more intensive adjuvant therapy and post therapy surveillance.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study. (Pubmed Central) - Dec 5, 2023
The outcome of patients with liver metastases appears to have improved in recent years. Patients with brain metastases had the worst PFS, which also did not improve over time.
- | Perjeta (pertuzumab) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Biopsy: Omission of Radiation in Patients With Her-2 Positive Breast Cancer (clinicaltrials.gov) - Dec 4, 2023
P=N/A, N=12, Terminated, Sponsor: University of Kansas Medical Center
Patients with brain metastases had the worst PFS, which also did not improve over time. N=78 --> 12 | Trial completion date: Dec 2026 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Mar 2023; Poor accrual and opening of competing national study (NRG-BR008 (HERO))
- | carboplatin / Generic mfg., docetaxel / Generic mfg.
Journal: Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer. (Pubmed Central) - Dec 4, 2023
In the neoadjuvant treatment of HER2-positive breast cancer, the docetaxel?+?trastuzumab?+?pertuzumab regimen might be more tolerated than the docetaxel?+?carboplatin?+?trastuzumab?+?pertuzumab regimen and did not show a lower complete pathological remission rate. However, our findings require further validation through prospective studies.
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Phase classification, Combination therapy, Metastases: DESTINY-Breast07: A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 3, 2023
P1/2, N=245, Active, not recruiting, Sponsor: AstraZeneca
However, our findings require further validation through prospective studies. Phase classification: P1b/2 --> P1/2
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade. (Pubmed Central) - Dec 3, 2023
Features of the response to therapy within the immune tumor microenvironment were recapitulated, including induction of an immune effector state with NK cell activation, enhanced cell apoptosis and decline of immunosuppressive PD-L1 immune cells. This work presents a unique human 3D model for the study of immune effects of anti-HER2 biologicals, which can be used to test novel therapy regimens and improve anti-tumor immune function.
- | Cosela (trilaciclib) / G1 Therap
Enrollment open: SMA-BC-002: Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (clinicaltrials.gov) - Nov 30, 2023
P2, N=116, Recruiting, Sponsor: wang shusen
This work presents a unique human 3D model for the study of immune effects of anti-HER2 biologicals, which can be used to test novel therapy regimens and improve anti-tumor immune function. Not yet recruiting --> Recruiting
- || Clinical data, Review, Journal: Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data. (Pubmed Central) - Nov 27, 2023
Not yet recruiting --> Recruiting We ultimately propose an evidence-based treatment algorithm for clinicians treating HER2
- | AST-302 / Aston Sci., EpiThany
Trial primary completion date, Surgery: Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer (clinicaltrials.gov) - Nov 18, 2023
P2, N=16, Recruiting, Sponsor: University of Washington
We ultimately propose an evidence-based treatment algorithm for clinicians treating HER2 Trial primary completion date: Oct 2023 --> Oct 2024
- ||| Perjeta (pertuzumab) / Roche
Journal, Adverse events: A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS). (Pubmed Central) - Nov 18, 2023
A significant association was detected between pertuzumab and some potential adverse events which should be regarded with some care. We have to pay attention to the first month after pertuzumab therapy and prepare emergency measures, especially for the elderly and patients with cardiovascular diseases.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. (Pubmed Central) - Nov 18, 2023
P2
Patients with confirmed partial response or stable disease (?4 months) in the CNS had stable PROs over time. Pertuzumab plus high-dose trastuzumab represents a reasonable non-chemotherapeutic treatment option for selected patients with HER2-positive MBC with CNS metastases.
- | Keytruda (pembrolizumab) / Merck (MSD), Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
New P3 trial, IO biomarker: OLIGAMI: Metastasis-directed Therapy for Oligometastases of Breast Cancer (clinicaltrials.gov) - Nov 18, 2023
P3, N=340, Recruiting, Sponsor: Tokyo Medical and Dental University
- | Herceptin (trastuzumab) / Roche
Journal: A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells. (Pubmed Central) - Nov 17, 2023
The novel nanobody-based HER2-targeted antibody, A9B5-Fc, binding to HER2-ECD I, mediates promising receptor internalization. It possesses the potential to serve as a potent synergistic partner with trastuzumab, contributing to overcoming acquired resistance.